Investor Relations

Investor Relations

Disrupting three healthcare segments with a value proposition non-existent in the current healthcare marketplace.

20+ patents granted in aging, wellness, exosomes and regenerative medicine that have successfully treated patients with outstanding outcomes, with standardized protocols to ensure product uniformity and regulatory compliance.

Leading experts across multiple disciplines leading to development of PranaX’s proprietary technology, achieving FDA approved clinical testing and extensive business building acumen.

Access to world renowned institutions and experts that will support awareness and adoption around PranaX’s line of products.

Exosome Banking (ExoSTORE™): Exosome banking is a groundbreaking service offered by PranaX. It involves collecting and preserving exosomes from various sources, such as placenta, umbilical cord blood and tissue, and circulating blood from individuals of all ages. Here's a more detailed breakdown:

  • Service Description: ExoSTORE™ provides individuals with the ability to bank their exosomes for future use, much like traditional cell banking services. PranaX collects, processes, and stores exosomes for clients, ensuring their availability for potential therapeutic applications down the road.
  • Market Demand: Exosome banking serves as a bio-insurance policy, safeguarding one's access to regenerative treatments in the future. Unlike traditional cell banking, exosome banking is more cost-effective and versatile, making it an attractive option for a broader range of applications beyond traditional cell-based therapies.
  • Benefits: Exosome banking boasts a strong safety profile, lower manufacturing costs, and a wide range of potential applications. It allows individuals to bank beyond birth and provides the final product for therapies. PranaX also offers whole genome and proteome sequencing of exosomes, enabling personalized regenerative treatments.
  • Pricing: The pricing for exosome banking is competitive, offering significant cost advantages compared to competitors, making it accessible to a broader customer base.

Exosome-Based Supplements (ExoWELL™): PranaX recognizes the demand for exosome-based supplements to support the well-being of healthy individuals. Here's an in-depth look at this revenue stream:

  • Service Description: ExoWELL™ manufactures exosome-based supplements designed to promote health and wellness in healthy individuals. These supplements are intended for use in health and wellness clinics as biological supplements. PranaX leverages FDA-approved technology for their production.
  • Market Demand: Exosomes have demonstrated a high safety profile in human trials, with no immune response. The market lacks prominent leaders in third-party exosome production and distribution to regenerative medicine clinics.
  • Benefits: Exosome-based supplements offer a safe, off-the-shelf wellness product for those seeking to enhance their overall well-being. PranaX's supplements are manufactured with a focus on quality and safety, making them suitable for a broad range of applications.
  • Pricing: The pricing for exosome-based supplements is competitive, with a significant gross margin. The revenue generation begins within 12 months of launching the products.

Exosome Stem Cell Therapy (PranaX Therapeutics™): This revenue stream focuses on harnessing the potential of exosomes to drive stem cell therapy, expanding patient access to high-quality exosomes.

PranaX is deploying the ExoWELL production process to supply clinical-grade exosomes for PranaX Therapeutics' upcoming FDA trials for various indications currently in development as well as for our current Bahamas clinical testbed.

In summary, PranaX's three revenue streams represent a comprehensive approach to leveraging the potential of exosomes in regenerative medicine. They cover a wide spectrum of applications, from banking exosomes for future use to providing supplements for wellness and offering advanced therapies through stem cell-derived exosomes. These revenue streams position PranaX as a leader in the emerging field of exosome-based regenerative medicine.